Företrädesemission tecknades till 17,4 procent

Företrädesemissionen i Panion Animal Health AB tecknades till cirka 1,3 miljoner kronor, motsvarande cirka 17,4 procent av emissionen. Med företrädesrätt tecknades 1 294 491 aktier, motsvarande cirka 16,8 procent. Panion tillförs därmed cirka 1,3 miljoner kronor före...

Panion’s market research initiative

Panion Animal Health is a veterinary drug company; the company’s business idea is to develop medicines and treatment methods that create a better life for animals. The first asset in development is a gene therapy to treat drug-refractory epilepsy in dogs. In addition,...

Panion’s presentation at the investor meeting 14. December 2018

The CEO of Panion, Anja Holm, presented the progress and the plans for the company’s development at the investor meeting held at Mangold offices in relation with the current share issue. Panion’s epilepsy project has just started the clinical phase with a pilot study...

Panion starts clinical study in dogs

Panion Animal Health AB develops a novel gene therapy treatment for dogs with epilepsy. The first clinical trial will be conducted at Long Island Veterinary Specialists, Ophthalmology, Surgery, Internal Medicine, Emergency, PLLC (“LIVS”) in New York, USA. It is a...